Home > Healthcare > Pharmaceuticals > Finished Drug Form > Oral Expectorant Market

Oral Expectorant Market Share

Report ID: GMI8788
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Oral Expectorant Market Share

The competitive landscape of the market is characterized by the presence of established companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective oral expectorant.

Oral Expectorant Market Companies

Prominent players operating in the oral expectorant industry are as mentioned below:

Abbott Laboratories
AstraZeneca
Cipla Inc.
Genexa Inc.
GlaxoSmithKline (GSK) plc
Merck KGaA
Perrigo Company plc
Reckitt Benckiser Group PLC
Sanofi
Sun Pharmaceutical Industries Ltd.
The Himalaya Drug Company

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global oral expectorant industry crossed USD 4.2 billion in 2023 and is expected to reach USD 5.7 billion by 2032, due to the increasing prevalence of respiratory diseases worldwide.

The secretion enhancer drug type segment held a decent share of the market in 2023 and is expected to grow at 3.7% CAGR between 2024 – 2032, driven by ongoing R&D in respiratory medicine.

North America oral expectorant market held a major share in 2023 and is anticipated to grow at 3.2% CAGR till 2032, due to its growing patient population and rising respiratory diseases.

Abbott Laboratories, AstraZeneca, Cipla Inc., Genexa Inc., GlaxoSmithKline (GSK) plc, Merck KGaA, Perrigo Company plc, Reckitt Benckiser Group PLC among others